Microsoft · After hours
Microsoft rallies as Azure growth accelerates
Microsoft rose roughly 4%–5% after hours after fiscal first-quarter revenue increased 19% to $92.3 billion and adjusted EPS reached $4.89. Azure revenue grew 48% to $33.2 billion, exceeding the company’s prior growth guidance.
Microsoft → Alphabet · After hours
Alphabet falls despite Google Cloud doubling
Alphabet dropped roughly 9% after hours. Revenue increased 25% to $127.6 billion and Google Cloud revenue surged 103% to $30.7 billion, but quarterly capital spending reached $51.4 billion and lower investment gains weighed on earnings.
Alphabet 8-K → Markets · Close
Major indexes finish modestly higher after the Fed pause
The S&P 500 gained 0.28% to 7,743.98, the Nasdaq Composite rose 0.27% to 26,549.85 and the Dow added 0.19% to 52,475.10. The Russell 2000 advanced 0.41%.
Bullstory → Federal Reserve · Decision
The Fed pauses, but two policymakers wanted another hike
The FOMC voted 10–2 to keep the federal-funds target at 3.75%–4.00%. The statement upgraded economic activity to a “strong pace” and said inflation remains elevated; Lisa Cook and Beth Hammack dissented in favor of a quarter-point increase.
Federal Reserve → Rates · Fed repricing
December-hike odds rise as Treasury yields move higher
Markets priced an 86% probability of a quarter-point December increase, up from 78.3% Tuesday. After the decision, the two-year yield was near 4.78% and the 10-year near 5.05%, both higher on the session.
Reuters via Investing.com → Breadth · Closing tone
Market breadth remains weaker than the headline indexes
Late-session decliners led advancers by 1.36-to-1 on the NYSE and 1.02-to-1 on Nasdaq. Nasdaq recorded 168 new lows against 67 new highs, confirming that the modest index gains were not broadly shared.
Reuters via Fidelity → Sectors · Leadership
Health care and financials lead while real estate lags
In the late-session sector snapshot, health care, financials and energy led on an equal-weighted basis. Real estate, communication services and materials lagged, while technology was nearly flat despite strength in memory stocks.
Bullstory → Energy · Settlement
WTI settles above $102 as supply risk returns
December WTI gained 2.9% to settle at $102.78 a barrel. December Brent was last up 1.5% at $115.59 after the reported Saudi refinery attack and a 1.9-million-barrel decline in U.S. crude inventories.
MarketScreener → Volatility · Risk appetite
The VIX declines despite the Fed and earnings catalysts
The VIX finished near 16.91, down about 3.5%. The decline suggests index-level hedging demand eased even as breadth remained soft and major technology earnings created sharp after-hours divergences.
Bullstory → Vertiv · AI infrastructure
Vertiv holds a double-digit gain after raising guidance
Vertiv was up about 14% at 12:29 p.m. ET after quarterly sales rose 61%, organic orders more than doubled and management raised its full-year sales forecast by $650 million. It was the strongest S&P 500 security in the midday snapshot.
Bullstory → GE Vernova · Earnings reaction
GE Vernova reverses lower despite surging orders
GE Vernova slipped about 1% by noon after initially rising on results. Orders increased 96% organically to $29 billion, backlog reached $197 billion and the company doubled its repurchase authorization to $20 billion.
GE Vernova → Enphase · Solar
Enphase tumbles after a weak fourth-quarter outlook
Enphase fell about 16% around noon after forecasting fourth-quarter revenue of $225 million–$255 million, below third-quarter revenue of $293.3 million. The company cited soft residential-solar demand, higher rates and an expired tax credit.
StockTitan → F5 · Guidance
F5 becomes the S&P 500’s sharpest decliner
F5 fell about 20% by 12:29 p.m. ET after forecasting fiscal-2027 revenue growth of 8%–9%, below the 11% pace reported for fiscal 2026. The reaction highlights the market’s low tolerance for slowing technology growth.
Bullstory → Genmab · Biotechnology
Genmab surges on positive Phase 3 data
Genmab gained about 29% around noon after its petosemtamab-plus-pembrolizumab combination reduced the risk of death by 50% versus pembrolizumab alone in a late-stage head-and-neck cancer study.
StockTitan → Wendy’s · Takeover proposal
Wendy’s jumps on a Trian-led buyout offer
Wendy’s rose about 16% around noon after Trian and partners submitted a non-binding $7.35-a-share acquisition proposal. The filing-driven move values the equity at roughly $1.4 billion and introduces a new transaction catalyst.
Charles Schwab →
Featured Article